MGC018 (B7-H3) versus Androgen Receptor Axis-targeted Therapy (ARAT) for people who have advanced prostate cancer, called metastatic castration-resistant prostate cancer (mCRPC).
A new generation of targeted drugs for treating advanced prostate cancer (PC) have come on the horizon. These drugs are referred to as antibody-drug conjugates or ADCs.
The challenge with cancer treatment is ensuring that the benefits (effectiveness) of the treatment outweigh the risks (side effects). For example, chemotherapy kills cancer cells but doesn’t entirely differentiate between cancer cells and healthy cells. Chemotherapy can damage healthy cells too leading to side effects like hair-loss, tiredness, and heart toxicity. Monoclonal antibodies are capable of a more selective anti-cancer treatment. ADCs combine the targeting power of antibodies and the advantages of chemotherapy. For patients this may mean potentially fewer side effects as the chemotherapy is preferentially delivered to the tumors with less chemotherapy delivered to normal tissues.
There are 3 parts to ADCs:
The Tamarack clinical trials are made up of two stages, Phase 2 and Phase 3:
Who can participate?
You will need to meet a few other criteria to take part in this study. The study team can explain these to you if you choose to learn more.
Some key exclusion criteria include:
The above is not an exhaustive list, for further information please speak to the study doctor.
To see if you may qualify for the TAMARACK study, you will attend one or more screening visits at the study clinic. You will be asked health-related questions and will have several study assessments, tests, and procedures to help determine if the study is a good fit for you.
TAMARACK Phase 2 Study:
If you are eligible, you will be randomly placed in either Group A, Group B, or Group C:
TAMARACK Phase 3 Study:
If you are eligible, you will be randomly placed in either Group A or Group B:
Randomly assigning you to one of these groups helps avoid bias in the study. Researchers can learn about safety and effectiveness by comparing the experiences of people in the different groups.
Possible patient benefits
Possible Patient risks
THE USE OF MG018 DESCRIBED HERE IS INVESTIGATIONAL SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED:
Clinical Trial Site:
Trials sites and contact can be found here.
If you are interested in this trial, review the following:
Clinicaltrials.gov Identifier: NCT05551117
Use the “clinical trials glossary” and “dictionary” for words, phrases, and treatments that you may not understand.